Latest News - AbbVie

Tuesday, September 04, 2018

AbbVie to Present New Data at 27th EADV Congress

AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12…

Read the full story

Friday, July 20, 2018

Game On: Head-to-head Trials to Enhance Competition in PsO Market

An increase in head-to-head trials will enhance the competition within the psoriasis market, according to GlobalData. The first major biologics that were released were anti-tumor necrosis factor (a…

Read the full story

Wednesday, January 17, 2018

GlobalData: Promising Future Forecasted for Dupixent

Regeneron Pharmaceuticals and Sanofi Genzyme’s Dupixent is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis on the market, according to GlobalData. Th…

Read the full story

Monday, January 08, 2018

FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitis

The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic derm…

Read the full story

Friday, October 27, 2017

Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studies

Top-line results from three pivotal Phase 3 clinical trials show that  risankizumab, an investigational interleukin-23 (IL-23) inhibitor, met the co-primary endpoints of at least a 90 percent imp…

Read the full story

Tuesday, August 29, 2017

FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseases

The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multip…

Read the full story

Thursday, July 27, 2017

Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humira

The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 4…

Read the full story

Thursday, March 30, 2017

FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to Humira Prescribing Information

The FDA approved the inclusion of moderate to severe fingernail psoriasis data in AbbVie's Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis…

Read the full story

Tuesday, May 03, 2016

Global Derm Market Set to Soar Through 2022

The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%, GBI Research reports. This rise will occur despit…

Read the full story

Wednesday, April 13, 2016

Psoriasis Market Poised for Growth Spurt by 2024

The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a new report from GlobalData. The market will rise from $6.6 billion in 2014 to over …

Read the full story

Thursday, September 10, 2015

FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativa

The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults wi…

Read the full story

Friday, May 15, 2015

AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa

AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hu…

Read the full story